Articles tagged with Drug Resistance
Researchers have discovered new drugs that can break resistance to Gab2 in CML cells, a type of blood cancer. The study found that sorafenib and axitinib are effective in treating CML model systems, providing potential alternatives for patients who have developed resistance to existing medications.
Biologists from UNIGE reveal a mechanism of resistance to the anti-estrogenic drug tamoxifen, identifying eight factors that enable breast cancer cells to become refractory to treatment. The researchers suggest various approaches for developing new therapies targeting these factors.
A new study reverses resistance to antiangiogenic drugs by adding an antidiabetic agent, inhibiting tumor growth up to 92%. Researchers found that this mechanism can be targeted to attack cancer cells, with potential for improved treatment outcomes. The discovery has the potential to prolong patient benefit from antiangiogenic treatments.
Researchers aim to identify genes involved in PZQ resistance, enabling development of simple molecular tests to monitor resistance and provide early warning of drug resistance emergence. The study will focus on precise genes and mutations in laboratory genetic crosses and then expand to field researchers in Uganda and Kenya.
Researchers developed an innovative imaging model to track drug resistance and identify a new therapeutic target for pancreatic cancer. The study revealed that the Musashi gene plays a critical role in promoting aggressive disease and found effective antisense inhibitors against Msi, halting tumor growth and improving survival.
A novel combination therapy has been found to clear the infection and prevent recurrence of babesiosis up to 122 days after treatment. The study used a mouse model to test the efficacy of atovaquone and ELQ-334, two drugs that work together to attack the parasite's target enzyme.
A research team at Georgia Institute of Technology identified a specific miRNA molecule that controls the genes governing chemotherapy resistance in human pancreatic cancer cells. Increasing this miRNA's level restored sensitivity to the drug in vitro, suggesting a potential therapeutic approach for battling chemotherapy resistance.
Researchers discovered that new malaria drugs promote premature parasite division by increasing sodium ion concentration, altering membrane composition and killing the parasite. The study found that these changes occur without replicating the parasite's genome, indicating a potential new mechanism of action for antimalarial drugs.
Researchers discovered how a new class of anti-cancer drugs, BET inhibitors, kill cancer cells through apoptosis. The findings explain how cancer cells may become resistant to treatment and provide potential strategies for developing improved therapies.
Researchers identified a specific enzyme and signaling pathway involved in resistance to treatment, which can be targeted by other drugs for improved outcomes. Glioblastoma multiforme tumors were shown to manipulate their surrounding environment to evade therapy, leading to longer survival when treated with combination therapies.
Researchers designed a novel mTOR inhibitor, Rapalink, to combat drug-resistant tumors. In animal experiments, Rapalink reduced the size of tumors resistant to earlier-generation inhibitors.
Primary aldosteronism is a common cause of high blood pressure that frequently goes undiagnosed and untreated. The Endocrine Society recommends expanded screening for individuals with high blood pressure, particularly those who are at higher risk, to prevent associated cardiovascular complications.
Researchers identified mechanisms that allow TRK-fusion lung cancer cells to evade targeted therapies. Specific genetic changes, including amino acid positions in TRK fusion genes, confer resistance to LOXO-101. This study's findings may have implications for other kinase-driven cancers treated with tyrosine kinase inhibitors.
Researchers at Johns Hopkins Medicine found that guadecitabine, when combined with standard chemotherapy, is safe and may overcome resistance to irinotecan in patients with metastatic colorectal cancer. The study showed stable disease for most patients and a partial response in one patient.
A new study found that parasites resistant to atovaqueone cannot pass this resistance on to their offspring, due to developmental defects and impaired reproduction. The research suggests that these mutations severely impair the parasite's lifecycle in mosquito hosts, preventing transmission.
Researchers at Queen Mary University of London have developed a modified flu virus that can re-sensitize resistant pancreatic cancer cells to chemotherapy. The virus enhances the efficacy of the drug by preventing cancer cells from repairing themselves, leading to increased cell killing with lower doses.
A new study reveals that a genetic mutation protecting malaria parasites against a key anti-malarial drug eventually kills them by stopping energy production. This discovery could improve malaria treatment and prevent mass drug resistance from spreading.
A team of researchers has identified an alternate mechanism for evading therapy in brain cancer cells, which adapts within as little as three days of treatment. By targeting both the original and new signaling pathways, they can durably suppress tumor growth.
Cancer researchers used single-cell phosphoproteomics to study glioblastoma and found that tumors adapt and resist therapies in as little as 48 hours. The approach could lead to personalized treatment with better combination therapies for this deadly brain cancer.
A metabolic pathway up-regulated in certain breast cancers promotes disease progression by activating the cell signaling protein Arf6, according to a recent study. Statin-like drugs may be effective treatments for patients whose tumors express high levels of Arf6 signaling proteins.
Researchers at Kumamoto University developed a method to predict epileptic seizures with high accuracy using electrocardiogram data. Heart rate variability analysis produced accurate predictions (91%) and allowed patients to ensure their safety before seizures. A wearable device is planned for development.
By treating individuals with a combination of drugs having different mechanisms of action, the chances of a malaria parasite developing multiple genetic mutations needed to survive is substantially decreased. This approach prolongs therapy effectiveness and preserves first-line drugs for treating malaria.
A new tool, IMPACT, interprets whole-exome sequencing data to identify candidate genes linked to cancer and recommends FDA-approved targeted treatments. The tool has been validated in patients with EGFR-mutated non-small cell lung cancer and melanoma, showing its potential to accelerate precision medicine.
Researchers found that curcumin successfully removes Mycobacterium tuberculosis from infected cells in culture by inhibiting the activation of nuclear factor-kappa B. The study suggests a potential new treatment for drug-resistant tuberculosis that could be less prone to resistance development.
Competition among malaria parasite strains in human hosts can influence the spread of drug resistance, according to a new study. The research found that when hosts are co-infected with drug-resistant and drug-sensitive strains, both strains are competitively suppressed, potentially leading to the emergence of resistant strains.
The Wellcome Trust Sanger Institute scientists discovered that the insertion of just two DNA bases into a gene helps the parasite overcome antimonial drug treatment. Whole-genome sequencing analysis revealed that the genetic landscape of L. donovani offers new insights into its evolutionary history and ability to develop drug resistance.
Researchers at Scripps Florida aim to block breast cancer growth by targeting a specific microRNA that adapts cancer cells to low oxygen environments. Inhibiting this microRNA increases the sensitivity of cancer cells to death and makes them more vulnerable to chemotherapy.
Researchers have identified a novel tyrosine kinase inhibitor that targets both resistant tumors and FLT3-independent AML. The compound, MRX-2843, exhibits antitumor effects in culture and preclinical models, improving survival rates even in cases of tumors resistant to existing treatments.
Researchers developed insights to guide powerful new anti-influenza drug development by analyzing artificially created drug-resistant flu strains' molecular details. The compounds target the endonuclease active site, a region where viruses can mutate to evade existing drugs.
A Cancer Research UK-funded study suggests an HIV drug could block the molecular switch that boosts cells' ability to survive treatment, making treatments more potent and delaying drug resistance. The research, carried out in mice, implies that nelfinavir could be used to combat melanoma skin cancers.
A new study finds that CDK4/6 inhibitor abemaciclib can restore sensitivity to HER2-targeted treatments in breast cancer cells, overcoming drug resistance. The agent's effectiveness was confirmed in mouse models and paves the way for a clinical trial.
A study published in the New England Journal of Medicine found that dihydroartemisinin-piperaquine (DP) was effective in preventing malaria in pregnancy, with no reported cases among women taking monthly doses. The therapy showed better results than sulfadoxine-pyrimethamine (SP), a widely used but ineffective option due to widespread ...
Researchers at Ohio State University have developed a DNA 'Trojan horse' that can deliver cancer drugs into resistant cells, effectively killing them. The capsule made of folded up DNA hides the invading force, allowing it to bypass cell defenses and accumulate in cancer cells.
Scientists have developed a new drug targeting the malaria parasite's proteasome, which could combat the growing resistance to first-defence treatments. The innovative approach has shown promising results in killing resistant parasites and may complement existing artemisinin drugs.
Analyzing tumor DNA fragments in the bloodstream can give a more complete picture of a patient's cancer. Researchers found that standard practice of performing molecular testing on a single metastatic lesion may be inadequate, and circulating tumor DNA testing may better capture the molecular diversity in a patient's tumor.
Scientists at Helmholtz Zentrum München discover that Cistus incanus extracts prevent human immunodeficiency viruses from infecting cells and block Ebola- and Marburg viral envelope proteins. The study demonstrates broad antiviral activity of Ci extracts against various major human viral pathogens.
A new study suggests that the standard practice of treating infections with high doses of anti-microbe medications may not be the best way to prevent drug resistance in all cases. The researchers found that using the highest dose that is safe may be more effective than using the lowest dose that is effective in preventing drug resistance.
A large study found tenofovir-resistant strains in 60% of HIV patients in sub-Saharan Africa, highlighting a significant concern for global HIV control strategies. The study suggests that up to 15% of HIV patients will develop resistance in the first year of treatment alone.
A recent study found that dihydroartemisinin-piperaquine treatment has failed in certain provinces of Cambodia due to parasite resistance. The WHO has reinstated artesunate plus mefloquine as the first-line treatment in these areas. New surveillance and clinical trials are needed to track the spread of piperaquine resistance.
Researchers have discovered a triple therapy approach that could make treatment-resistant lung cancers susceptible to therapy. The combination of two experimental drugs and radiation therapy was found to be effective in mice with KRAS-related gene mutations.
Researchers discovered a novel mechanism of resistance and re-sensitization to first-generation ALK inhibitors in a patient with metastatic non-small-cell lung cancer. The study highlights the importance of repeat biopsies and molecular profiling to uncover novel resistance mechanisms.
A team of NUS researchers discovered over 120 protein targets of artemisinin in Plasmodium falciparum, the most pathogenic malaria parasite. The study found that haem is the main activator of artemisinin, which targets essential biological processes in the parasite.
A Georgetown University Medical Center researcher is leading a multi-institutional effort to investigate the causes of rising drug-resistant malaria parasites. The study aims to understand molecular mechanisms responsible for this increasing resistance and develop new therapies.
Researchers found that combining palbociclib with paclitaxel shrank tumors in nearly half of patients with estrogen-receptor positive breast cancer. The combination appears to be safe and may offer benefits over paclitaxel alone, suggesting a larger clinical trial is warranted.
Researchers at Eindhoven University of Technology have identified a novel site on the RORγt nuclear receptor that can be targeted by drugs without inducing resistance. This discovery could lead to new treatments for autoimmune diseases like rheumatism and Crohn's disease.
Researchers identified 13 hotspot CNVs associated with JME and found that drug resistance enriches a clinical cohort for common CNVs. This study provides new insights into the genetic basis of JME and highlights the need for further molecular biology studies.
Studies reveal that different types of autoimmune responses elicit distinct responses in patients with drug-resistant epilepsy. Antibodies targeting intracellular proteins lead to a worse prognosis and poorer response to immunotherapy compared to those against cell surface proteins.
A team of researchers developed a model to predict the effects of parasite refugia on disease prevalence and drug resistance. The model suggests that introducing drug-susceptible parasites into a population can reduce overall drug resistance.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a promising new melanoma drug, SBI-756. The compound targets the translation initiation complex and has been shown to inhibit melanoma cell growth. SBI-756 may offer a significant advantage in overcoming tumor resistance.
A mass drug administration (MDA) program implemented in Southern Greece eliminated malaria cases for two years, preventing a resurgence of the disease. The MDA covered 87% of an immigrant population and was effective in minimizing the risk of drug resistance.
A Vanderbilt study found that sildenafil improves insulin sensitivity in people at risk for diabetes, potentially reducing the risk of developing type 2 diabetes. The researchers discovered that sildenafil inhibits an enzyme called phosphodiesterase 5, resulting in relaxation of smooth muscle and increased blood flow.
Researchers have discovered a new mechanism of drug resistance in metastatic prostate cancer cells, which can be predicted using protein levels. The study found that high levels of 4EBP1 protein lead to decreased protein synthesis and resistance to PI3K pathway inhibitors.
A 2-year-old girl was diagnosed and treated for XDR TB, the first detailed account of a young child in the US. The successful treatment highlights the need for better understanding and creative approaches to pediatric tuberculosis.
A computer simulation study suggests that treating malaria with a combination of more effective and less effective drugs can slow the spread of drug-resistant parasites. The non-artemisinin therapy, even when only 85% effective, works best in this approach.
Researchers have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug. The test predicts which patients will not respond to treatment and can inform personalized treatment options.
Researchers identified VRAC channels as responsible for half of anti-cancer drug uptake, with down-regulated subunits linked to therapy resistance and programmed cell death disturbances. The study's findings hold high clinical relevance and suggest potential new targets for overcoming cancer therapy resistance.
Researchers explored the use of ivermectin in mass drug administration campaigns to reduce malaria infections in Africa and slow down drug resistance in Asia. Preliminary results showed a 16% reduction in childhood malaria episodes in Burkina Faso, where most population members received regular ivermectin doses.
A study found that sirolimus successfully resolved autoimmune conditions in children with ALPS without adverse side effects. The treatment improved blood cell counts and quality of life for patients, making it a potential early therapy option.
Researchers found developing resistance to miltefosine in patients with post-kala-azar dermal leishmaniasis, leading to higher relapse rates. The study suggests a pressing need for new therapies to combat drug-resistant strains of the disease.
A study published in the Journal of Virological Methods found that Bio-Rad's Droplet Digital PCR (ddPCR) technology significantly increases the sensitivity and precision of mutation abundance quantification when compared to RT-qPCR. This makes it an ideal tool for detecting viral RNA mutations in clinical samples.